Study drug for agitation in Alzheimer’s dementia with caregiver support
Part of Brain & nervous system, Mental health clinical trials.
This Phase 2 trial tests a study medicine to reduce “agitation” behaviors in people with Alzheimer’s dementia. You and your caregiver would complete required assessments and may need genetic and blood testing to check how the body handles the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legally allowed representative) must sign an informed consent form before any study steps.
- A known caregiver must be available and willing to follow study steps, including using a phone or video calls and learning basic health checks like blood pressure.
- The participant must have Alzheimer’s dementia and ongoing, clinically significant agitation (not just new or occasional episodes).
- You must agree to genetic testing (APOE) and a blood test plan for how the body processes the medicine (pharmacokinetics).
- Urine drug screening must be negative (except benzodiazepines if used steadily for months, per the rules), and key behavior-related medicines must be stable for about 6 weeks before starting.
- Women must be unable to become pregnant (for example, postmenopausal or surgically unable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
This Phase 3 trial studies whether nabilone can reduce agitation (restlessness, anger, or difficult behavior) in people with Alzheimer’s dementia. It’s designed for older adults who already have agitation despite standard dementia care.
This study tests if a CBD medication can help reduce agitation in people with Alzheimer's disease. It's for adults 55 and older who have significant agitation and mild to moderate dementia.
This trial studies treatment for troubling nighttime restlessness and agitation in people with Alzheimer’s disease. It may help improve sleep and nighttime comfort and reduce nighttime behavior problems.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
Hear when a new Agitation,Psychomotor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.